Axillary Nerve Block Combined With Suprascapular Nerve Block (SSNBANB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02060812|
Recruitment Status : Completed
First Posted : February 12, 2014
Last Update Posted : February 12, 2014
Purpose: The purpose of this study is to compare the result of combined sono-guided suprascapular nerve block (SSNB) and axillary nerve block (ANB) with isolated SSNB in postoperative pain following arthroscopic rotator cuff repair. Our hypothesis was that SSNB combined ANB would show a more effective anesthesia for arthroscopic rotator cuff repair as compared with SSNB only.
Methods: Forty-two patients with rotator cuff tear who had undergone arthroscopic rotator cuff repair were enrolled in this study. Among them, 21 patients were randomly allocated into group I, and received SSNB and ANB with each 10mL ropivacaine. The other 21 patients were allocated into group II, and received SSNB with 10mL ropivacaine and ANB with 10mL normal saline. Visual Analogue Scale (VAS) pain score, patient's satisfaction (SAT), and Lateral Pain Index (LPI), etc was checked at postoperative 1, 3, 6, 12, 18, 24, 36, and 48 hours.
|Condition or disease||Intervention/treatment||Phase|
|Rotator Cuff Tear||Procedure: Group I, SSNB & ANB Procedure: Group II, SSNB alone||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Sono-guided Suprascapular Nerve Block Combined With Axillary Nerve Block in Arthroscopic Rotator Cuff Repair: a Randomized Controlled Trial|
|Study Start Date :||November 2012|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||October 2013|
Experimental: Group I, SSNB & ANB
21 patients were randomly allocated into group I, and received suprascapular nerve block (SSNB) and axillary nerve block (ANB) both with 10mL ropivacaine.
Procedure: Group I, SSNB & ANB
Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
Placebo Comparator: Group II, SSNB alone
The other 21 patients were allocated into group II, and received suprascapular nerve block (SSNB) with 10mL ropivacaine and axillary nerve block (ANB) with placebo (10mL normal saline).
Procedure: Group II, SSNB alone
This is same as the Group I, SSNB & ANB, but ANB was performed with placebo(10mL normal saline).
- Visual analogue pain scale [ Time Frame: postoperative 48 hours ]VAS pain score was selected from 0 to 10. 0 was no pain and 10 was severe pain that the patient had ever experienced.
- Patient satisfaction (SAT) [ Time Frame: postoperative 48 hours ]SAT was also selected from 0 to 10. 0 was unsatisfactory and 10 was very satisfactory.
- lateral pain index (LPI) [ Time Frame: postoperative 48 hours ]The percentage of lateral pain was determined as a value between 0 and 100. LPI was determined as VAS pain score × the percentage of lateral pain of shoulder ÷ 100.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02060812
|Korea, Republic of|
|Chuncheon Sacred Heart Hospital|
|Chuncheon-si, Gangwon-do, Korea, Republic of, 700-204|
|Principal Investigator:||Jung-Taek Hwang, MD, PhD||Chuncheon Sacred Heart Hospital|